Other 🇩🇰, Denmark
Novo Nordisk develops and manufactures medicines for diabetes and obesity, including Ozempic and Wegovy (semaglutide). Its GLP-1 business includes injectable and oral formulations. This profile follows its product launches, commercial expansion and financial updates as it competes for patients and market share.
As of 2026-09-14 · USD · Recorded monthly observations
Last 12 months
Last 12 months
Novo Nordisk says its experimental CagriSema injection produced more weight loss than a tested dose of Lilly’s tirzepatide in adults with type 2 diabetes. The comparison does not cover every available dose.
Fierce Pharma reported record weekly prescriptions for Novo’s Wegovy pill and Lilly’s Foundayo. The figures track prescriptions, including refills, rather than new patients or comparative treatment results.
Novo Nordisk has launched the daily tablet version of Wegovy in Germany, Reuters reported. The launch brings the weight-management medicine to its first European Union market in pill form.
Novo NordiskNovo Nordisk now expects a smaller decline in annual sales, citing improved expectations for diabetes and weight-loss medicines. The revised forecast still ranges from a 6% fall to no growth.
Novo NordiskGrow revenue at each location and build a commercial model that can scale across a clinic group.
Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.
SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.
SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.
All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.
